EVerZom raises €10 million to accelerate the development of exosome-based biotherapies

EVerZom , a French company pioneering exosome-based therapies for regenerative medicine applications, announces a €10 million fundraising round. This round was completed with support from Capital Grand Est, the European Innovation Council (EIC) Fund, Sorbonne Venture by Audacia , Aloe Private Equity, Paris Business Angels, the Capital Cell platform, and several family offices.

This transaction marks a decisive step for EVerZom, which is now preparing for the clinical entry in 2026 of its flagship drug candidate EVerGel™, intended for the treatment of complex perianal fistulas linked to Crohn’s disease. At the same time, the company is strengthening its exosome bioproduction platform to GMP standards and expanding its research into new therapeutic indications, particularly in hepatology and dermatology.

“Our ambition is to bring the therapeutic potential of exosomes to patients in pathologies with high medical needs. This fundraising allows us to lay the foundations of an industrial and partnership platform capable of bringing about a new therapeutic class,” emphasizes Jeanne Volatron, co-founder and CEO of EVerZom.

Exosomes, biological nanoparticles secreted by cells, represent a breakthrough approach in the field of biotherapies. As natural messengers of intercellular communication, they pave the way for innovative treatments for many diseases where medical needs remain unmet.

With this funding, EVerZom also intends to expand its technology through strategic partnerships with the pharmaceutical industry and explore new indications. A winner of the France 2030 plan in 2025, the company also benefits from €3 million in support to accelerate the industrialization of its platform.

Read the full press release for more information on this fundraising round and EVerZom’s ambitions.